Agonist News and Research

RSS

Breakthrough discovery opens doors for targeting adhesion GPCRs with drugs

Almost 35% of drugs approved by the Food and Drug Administration work by targeting G protein-coupled receptors (GPCRs), proteins embedded in cell membranes that allow cells to communicate with each other.

18 Dec 2024

Obesity prevalence and BMI decrease in the US for the first time in a decade

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.

16 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024

The brain’s hunger switch: TRH neurons hold the key to obesity therapies

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based obesity treatments.

9 Dec 2024

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets don't work.

2 Dec 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

27 Nov 2024

Anti-obesity drugs increase food waste in some users

Taking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has found.

22 Nov 2024

Ingestible capsule releases a burst of drugs directly into the walls of the GI tract

Inspired by the way that squids use jets to propel themselves through the ocean and shoot ink clouds, researchers from MIT and Novo Nordisk have developed an ingestible capsule that releases a burst of drugs directly into the wall of the stomach or other organs of the digestive tract.

21 Nov 2024

More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

20 Nov 2024

New protein target offers promise for alleviating cognitive decline in Parkinson's disease

A recently published study by researchers at the University of Arizona Health Sciences found that a tiny protein called PNA5 appears to have a protective effect on brain cells, which could lead to treatments for the cognitive symptoms of Parkinson's disease and related disorders.

19 Nov 2024

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, that are being simultaneously presented at the American Heart Association's 2024 Scientific Sessions.

19 Nov 2024

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

19 Nov 2024

How vitamin B3 could be the secret to living longer and protecting your heart

Dietary niacin intake reduces risks of all-cause and cardiovascular mortality in US adults, with benefits more pronounced in non-diabetic individuals and linked to NAD metabolism improvements.

18 Nov 2024

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, warranting further clinical investigation.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024